FOXO4-DRI
FOXO4 dominant-negative interfering peptide. Selectively triggers apoptosis in senescent cells by disrupting FOXO4-p53 interaction. Animal-model senolytic with strong age-reversal data in mice.
FOXO4-DRI: FOXO4 dominant-negative interfering peptide. Selectively triggers apoptosis in senescent cells by disrupting FOXO4-p53 interaction. Animal-model senolytic with strong age-reversal data in mice. FOXO4-DRI is a senolytic peptide, it selectively kills senescent ('zombie') cells that accumulate with age and drive inflammation.
FOXO4-DRI is a senolytic peptide, it selectively kills senescent ('zombie') cells that accumulate with age and drive inflammation. The mouse data is dramatic: improved fur, kidney function, fitness in old mice. Human data is essentially nonexistent.
Who it's for
- →Researchers studying senolytics
- →Longevity-research contexts under medical guidance
- →Educational reference, limited human safety data
What to expect
- Week 1
Mouse-model markers (improved fur density, kidney function, fitness) emerged within 10 days.
- Week 4
Off-pulse. Effects in mice persisted for weeks.
- Week 8
No human long term data exists.
Looking at FOXO4-DRI? Your next 3 steps
- 1Work out your syringe units
Vial size + BAC water turns into the exact units to draw for FOXO4-DRI.
Open calculator → - 2See what to stack & monitor
The companion supplements and the bloodwork worth tracking on this kind of protocol.
Bloodwork guide → - 3Save it & ask the Coach
A free account gets you Coach questions every day, free; membership saves your stack and makes the Coach stack-aware.
Create free account →
How it works (mechanism)
Dominant-negative interfering peptide that disrupts the FOXO4-p53 interaction. In senescent cells, FOXO4 normally protects against p53-driven apoptosis; blocking the interaction selectively triggers death of senescent ('zombie') cells.
Dosing protocol
Stacks well with
Side effects
When NOT to use
- ⚠Active malignancy (apoptotic effects on cells in unstable states)
- ⚠Pregnancy / nursing
- ⚠Anyone risk-averse to pre-clinical-only data
Bloodwork to monitor
- • CBC and basic metabolic panel if researching
Common mistakes
- • Treating it as a longevity 'drug' (it's pre-clinical)
- • Running long cycles instead of short pulses
- • Stacking with other experimental compounds
What it actually is
FOXO4-DRI is a designed peptide built to kill senescent cells — cells that have stopped dividing but refuse to die, and which accumulate with age while secreting inflammatory signals. It is built in retro-inverso form, meaning the sequence is reversed and made of mirror-image D-amino acids, which makes it resistant to breakdown. It is preclinical, with zero human trials, and the mouse results that made it famous are genuinely striking.
Senescent cells survive because they keep p53, the protein that would normally trigger their death, sequestered by FOXO4. FOXO4-DRI competes for that interaction and displaces p53, which then does what it was going to do and kills the cell. Because healthy cells do not depend on that sequestration, the effect is meant to be selective for senescent ones. In aged mice, pulsed dosing restored fur density, kidney function and fitness. A 2025 Nature Communications paper further characterised the p53 domain involved.
Forms, and which is which
Mouse protocols pulse it every other day for three doses. There is no established human dose.
Verdict: The honest description of where this is.
Buyer reconstitutes. A D-amino acid retro-inverso peptide is also unusually hard to verify by any means available to a buyer.
Verdict: Unverified material with no human dose behind it.
Other senolytic approaches that have reached early human trials, which this has not.
Verdict: The same idea further along.
Combines an untested compound with others, making anything observed unattributable.
Verdict: Several unknowns at once.
What it is claimed to do, graded
Demonstrated in cell and animal work, and the mechanism was further characterised in a 2025 Nature Communications paper. Genuine laboratory science.
The famous result: restored fur density, kidney function and fitness in aged mice with pulsed dosing. Real, and in mice.
Zero human trials of any kind.
Worth stating carefully. A 2023 Circulation paper found that eliminating senescent cells can PROMOTE pulmonary hypertension development in a model. Senescence is not purely a defect to be cleared, and this is a result from the senolytic field itself.
No human safety data. A peptide that triggers apoptosis has obvious potential for off-target cell death and nobody has measured it in a person.
Grades describe how much human evidence exists for that specific claim, not whether it will work for you or whether it is safe.
Pros and cons
- • One of the most striking mouse results in the ageing field, and a genuinely elegant mechanism
- • Pulsed dosing rather than continuous, which limits exposure
- • Retro-inverso design gives real resistance to breakdown
- • Published in high-quality journals
- • Zero human trials — grade D on the site's own ladder
- • No human dose exists; the mouse protocol is per kilogram and not translatable
- • Clearing senescent cells is not uniformly good — one model found it promoted pulmonary hypertension
- • Triggering apoptosis is a blunt instrument with untested off-target potential
- • Research-chemical supply of an unusual peptide chemistry that cannot be verified
When to stop
- • Any new or unexplained symptom during or after a pulse
- • Breathlessness on exertion that is new
- • Any new cancer diagnosis
- • You are running it continuously rather than in short pulses
Interactions
Cells in unstable states respond unpredictably to an apoptotic trigger, and senescence is also one of the body's brakes on tumour formation.
Compounding apoptotic pressure with no way to attribute an effect or a harm.
A specific model finding that senescent cell clearance can worsen this. Not a generic caution.
Overlapping apoptotic mechanisms, entirely unstudied together.
There is no human interaction literature for this compound.
Is this for you?
- • Laboratory research. There is no human dosing basis, and the senolytic field's own results show the effect is not uniformly good
- • You have active cancer or any undiagnosed lump
- • You have pulmonary hypertension or pulmonary vascular disease
- • You are pregnant or nursing
- • You want a dose you can trust — none exists
The one number
Sources for the claims above
- Eliminating senescent cells can promote pulmonary hypertension development
- The disordered p53 transactivation domain as the target of FOXO4 and the senolytic
- Targets extracellular matrix production in fibroblasts
New to FOXO4-DRI? Grab the starter checklist.
Drop your email and we'll send the one-page starter checklist beginners actually need first. No account needed.
No spam, and we never sell your email. Just the checklist. Email support@pepdex.co to opt out any time.
Numbers redacted in this preview. Members get the full answer, on their own stack.
Ask the Coach anything about FOXO4-DRI or your own stack. This is it working.
Trained only on Pepdex content. Does the dose math, flags interactions, knows your stack. Won't push vendors, won't pretend to be a doctor.
Unlock the full Coach, from $4.99/week →Frequently asked
What is FOXO4-DRI?+
Is FOXO4-DRI FDA approved?+
Is FOXO4-DRI legal?+
Is FOXO4-DRI banned by WADA?+
Are you still natty after taking FOXO4-DRI?+
Do doctors prescribe FOXO4-DRI?+
What's the typical dose of FOXO4-DRI?+
What are the side effects of FOXO4-DRI?+
How long until FOXO4-DRI starts working?+
What can you stack with FOXO4-DRI?+
Where do people get FOXO4-DRI?+
Common questions about FOXO4-DRI
Tracked alongside FOXO4-DRI
Same goal, different aisle — each graded on its own evidence in the Pepdex catalog.
More in Longevity
Studied as an anti-aging and sleep-cycle peptide. A tetrapeptide derived from epithalamin, looked at for telomerase activation and circadian / pineal support, with limited human data.
Aimed at brain aging and your body clock. A Russian-origin tripeptide (Glu-Asp-Arg) with limited human data, so treat it as experimental.
A compound studied for protecting the brain and keeping cells alive and insulin-sensitive as you age. A mitochondrial-derived peptide encoded inside mitochondrial DNA, studied for neuroprotection, insulin sensitivity, and cellular survival.
A family of short (2-4 amino acid) peptides developed at the St. Petersburg Institute of Bioregulation and Gerontology. Tissue-specific organ-support peptides: Cartalax, Cardiogen, Cortagen, Chonluten, Livagen, Ovagen, Pancragen, Prostamax, Testagen, Thymogen, Thymulin, Vesugen, Vesilute, Vilon, Bronchogen (Broncogen). Limited Western clinical data.